Amber Tong is a Senior Editor at NXTmine. She covers a wide range of topics within the realms of medicine and healthcare, including biotech, diagnostics, and alternative medicine, while also addressing significant issues like the FDA and the impact of the Coronavirus on the healthcare system. Amber's work has been featured in prominent publications such as Endpoints News, Boston Globe Technology, Financial Advisor Magazine, The Irish Times, Bloomberg News, BNN Bloomberg, and The Spokesman-Review.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Amber's coverage mainly focuses on healthcare and pharmaceuticals, with a significant emphasis on company announcements and clinical trial outcomes. She appears to be particularly interested in developments within the pharmaceutical industry, including drug development, clinical trials, and company acquisitions.
Given her focus on private sector announcements and press releases, Amber may be more responsive to pitches related to exclusive news from within the pharmaceutical industry or expert insights into major developments such as clinical trial results or company strategies.
It is important to note that Amber does not seem to have a specific geographic focus but rather provides comprehensive coverage of global pharmaceutical industry developments.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Ashleigh Furlong, Amber Tong
At a time when geopolitical tensions are hitting industries from semiconductors to electric vehicles, pharmaceutical dealmaking has become a rare bright spot for collaboration between China and the West. Industry watchers are holding their breath to see how the incoming Trump administration changes that.
Sanofi SA will invest around 1 billion euros ($1.1 billion) to build a new insulin production base in Beijing, its biggest single investment in China to date and part of a broader push to boost manufacturing capacity in Asia.
Shares of WuXi AppTec Co. and WuXi Biologics Cayman Inc. surged Monday, after a draft US legislation targeting the Chinese biotechnology service firms was left out of a key defense bill.
Even as Americans live longer, they spend more of their years in poor health than any other country, a new study shows.
By: Amber Tong
December 11, 2024 Even as Americans live longer, they spend more of their years in poor health than any other country, a new study shows.
China’s aggressive drive to replace brand-name foreign drugs with dirt-cheap homegrown generics has already taken a toll on global pharmaceutical companies’ local business. Now they’re almost nowhere to be found on the latest list of companies winning contracts to sell commonly-used drugs to Chinese hospitals.
WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese company seeks to enhance its margins while continuing to navigate geopolitical tensions.
WuXi AppTec Co. and WuXi Biologics Cayman Inc. said they see a brighter 2025 for the Chinese biotech and drug companies after the US Biosecure legislation that threatened to cut them out from their biggest market failed to pass.
Some of China’s senior doctors are raising concern over the quality of domestic generic medicines that have largely replaced western brand-name drugs at hospitals, amid a rare public backlash against the government’s drive to cut medical costs.
By: Amber Tong
Hi, it’s Amber in Hong Kong. For many of us, drug labels can be impossible to decipher. A small change may help. But before I explain…
(833) 317-6278 
